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ABSTRACT
Objective: The objective of the study was to evaluate the role of the herbal immunomodulators Immusante and Guduchi in boosting the immunity and 
overall health of healthcare workers assigned to coronavirus disease 2019 (COVID-19) wards.
Methods: An open-label, randomized, prospective, and single center clinical study was conducted among 100 healthcare workers assigned to 
COVID-19 wards. Eligible subjects (50 in each arm) were randomly assigned to either arm I (Immusante+Guduchi tablets) or arm II (treatment as 
per the institutional policy). Assessments after 30 days of treatment included respiratory symptoms, Adapted Immune Status Questionnaire (ISQ), 
improvement in quality of life (Short form 12 [SF-12] Health Survey), and safety and tolerability.
Results: All 100 subjects completed the study as per the protocol. There were no respiratory symptoms in the subjects in arm 1. However, four 
subjects (8%) in arm II reported cough during the study period. A better Immune status improvement was seen through the adapted ISQ in arm I 
as compared to arm II. In each of the 8 SF-12 Health Survey domains, a statistically significant difference was observed in arm I compared to arm II. 
A retrospective assessment of COVID-19 infection showed only 8% of subjects as COVID-19 positive in arm I compared with 26% of subjects in arm II.
Conclusion: Considering the positive trend observed in this study in terms of ISQ, SF-12, and COVID-19 infection rates, the combination of Immusante 
and Guduchi in healthcare workers at a high risk of contracting COVID-19 infection had a beneficial effect in boosting immunity and overall health.
Keywords: Coronavirus disease 2019, Herbal immunomodulators, Tablet immusante, Tablet Guduchi, Healthcare workers.
INTRODUCTION
The novel coronavirus 2019, severe acute respiratory syndrome 
coronavirus 2, or coronavirus disease 2019 (COVID-19) was first 
reported in the city of Wuhan in China and later spread worldwide. 
It was declared a pandemic on March 11, 2020, by the World Health 
Organization (WHO) because of its global spread, rapid transmission, 
and the critical nature of many cases.
Healthcare workers are at a high risk of contracting communicable 
diseases such as COVID-19 as they perform high-risk activities and 
spend a lot of time caring for infected patients. Maintaining a healthy 
immune system is key to preventing infection and disease. Considering 
the high vulnerability of healthcare workers, it is necessary to provide 
priority access to testing, treatment, and immunization.
Ayurveda and allied systems of medicine consist of a large repertoire 
of herbal medicinal agents that may offer a solution to this health 
care challenge. In recent years, individual herbs as well as polyherbal 
combinations that help in promoting immunity and respiratory health 
have undergone rigorous scientific and clinical scrutiny to establish 
their efficacy and safety. Two examples of potentially helpful herbal 
agents are Immusante (Prosopis glandulosa 150 mg and Symplocos 
racemosa 100 mg) and “Guduchi” (Tinospora cordifolia) tablets and are 
manufactured at Good Manufacturing Practice certified facilities with 
adherence to Good Agricultural and Collection Practices (as per the 
WHO guidelines). Standardization of the production protocol minimizes 
batch-to-batch variation and assures the safety, efficacy, and quality of 
these products. Both products have undergone rigorous preclinical and 
clinical studies for immunotherapeutic support. With this background, 
the possible roles of Immusante and Guduchi tablets in boosting 
immunity to COVID-19 are evaluated in this exploratory study.
Immusante is a broad-spectrum immunomodulator developed after 
decades of research on herbs mentioned in classical Ayurvedic texts. 
Immusante tablets are recommended as immunotherapeutic support 
in immunocompromised conditions such as viral and opportunistic 
infections. These tablets augment immune function, attenuate disease 
manifestation, and improve resistance to disease. Immusante is 
known to upregulate interferon gamma [1], fight viral infection, have 
antioxidant properties, modulate both cellular and humoral immunity, 
improve the function of neutrophils and macrophages and in turn 
phagocytosis, augment CD4+ cell count, and promote cytokine gene 
expression relevant to immunomodulation.
Guduchi, popularly known as “Amrutha” (meaning “nectar” in Sanskrit) 
in Ayurveda, is an herbal treatment used for fever, infections, and 
promoting immunity. The immunomodulatory effects of Guduchi have 
been extensively studied through different experimental models and 
have also been validated by clinical studies for multiple indications [2]. 
Guduchi has been found to be effective in relieving the clinical symptoms 
of allergic rhinitis, cold, and fever, thereby boosts immunity [3]. Guduchi 
exerts an immunomodulatory effect through macrophage activation and 
anti-inflammatory effects by inhibiting the expression of inflammatory 
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cytokines (such as tumor necrosis factor -α and interleukin -1β) and 
decreasing nitric oxide production.
This study was conducted to evaluate the role of the herbal formulations 
Immusante and Guduchi in boosting the immunity and overall health of 
healthcare workers assigned to COVID-19 wards.
METHODS
An open-label, two-armed, randomized, and prospective clinical study was 
conducted at Victoria Hospital, Bangalore Medical College and Research 
Institute (Bengaluru, Karnataka, India). The study was conducted in 
accordance with ethical standards and the Helsinki Declaration after 
obtaining approval from the ethics committee of the Bangalore Medical 
College and Research Institute and registration with the Clinical Trials 
Registry of India (CTRI/2020/07/026579). Informed, signed consent was 
obtained after a careful explanation of the study from all enrolled subjects.
The inclusion criteria were male and female subjects who were 18–
60 years old, individuals at a high risk of contracting COVID-19, and 
community healthcare workers who were assigned to COVID-19 wards. 
The main exclusion criteria were current active, confirmed, or relapsed 
COVID-19–positive individuals, pregnant or lactating women, those with 
a recent history of lung diseases such as asthma and chronic obstructive 
lung disease, those unable to take oral medications or suffering from 
ailments related to absorption, those with immunocompromised 
conditions or taking any immunosuppressant therapy, and subjects 
suffering from severe and uncontrolled metabolic/endocrinal/cardiac/
renal/hepatic disease, on the basis of history and clinical judgment by 
the investigator. A randomization list was generated by a biostatistician 
using online software using the block randomization method with a 
block size of 4, and the subjects were randomized into two arms.
After providing informed consent, a total of 100 subjects who fulfilled 
the eligibility criteria were enrolled and randomized into the two 
treatment arms in a 1:1 ratio (50 subjects in each arm). Subjects 
assigned to arm I received Immusante and Guduchi at a dose of 1 oral 
tablet each, twice daily for 30 days. Subjects in arm II did not receive 
any treatment to boost immunity. Clinical assessments were performed 
at the baseline visit (screening day 1) and subjects were followed up 
and assessed on all subsequent visits, that is, visit 2 (day 7±3 days; an 
optional telephone visit [TO]), visit 3 (day 14±3 days or TO), visit 4 (day 
30±3 days, End of study or TO), and visit 5 (day 45±3 days, follow-up 
visit, or TO). Either visit 4 or visit 5 was required to be an on-site visit. 
Assessment of immune status based on the Adapted Immune Status 
Questionnaire (ISQ) was performed on visits 1, 3, 4, and 5.
The Short form 12 (SF-12) Health Survey SF-12 is the abridged 
practical version of the 36-item Short Form Health Survey (SF-36), 
which was developed as a tool for measuring health-related quality 
of life. SF-12 was assessed on visit 4. The questionnaire contains eight 
domains comprising of 12 items, covering overall physical and mental 
health: Physical functioning (2 items), role limitations due to physical 
problems (2 items), body pain (1 item), general health perceptions (1 
item), vitality (1 item), social functioning (1 item), role limitations due 
to emotional problems (2 items), and mental health (2 items). SF-12 
summarizes the responses into a physical component summary (PCS) 
and a mental component summary (MCS).
Statistical analysis of the data generated in this trial was analyzed using 
GraphPad Prism software v. 6.07 (San Diego, CA, USA). As this was an 
exploratory feedback study, no formal sample size estimation was done. 
Means and standard deviations (SD) were calculated for continuous 
variables, and frequencies and percentages are reported for categorical 
variables. Normally distributed continuous variables were compared 
using repeated measures analysis of variance followed by a post hoc test, 
whereas variables with a non-normal distribution were compared using 
the nonparametric Friedman test followed by a post hoc test. Within-group 
analysis was performed by the Friedman test followed by Dunn’s multiple 
comparisons test, and between-group comparisons were assessed using 
the Mann–Whitney test. The SF-12 Health Survey was analyzed by an 
unpaired t-test. For comparisons between groups, continuous variables 
with a normal distribution were compared using the unpaired t-test, 
whereas variables with a non-normal distribution were compared using 
the Mann–Whitney test. All statistical tests used a significance level of 
p≤0.05. Two-tailed tests were performed for all analyses.
RESULTS
Study subjects
All 100 subjects completed the study according to the study plan, and the 
study drugs were analyzed for their impact on boosting the immunity 
and overall health of healthcare workers assigned to COVID-19 wards. 
Detailed baseline demographics of all subjects in the study are reported 
in Table 1. The flow diagram of the study as per the Consolidated 
Standards of Reporting Trials guidelines is depicted in Fig. 1.
Clinical assessment
At baseline (visit 1), ten subjects in arm I had sore throat, cough, runny 
nose, nausea, diarrhea, rash, muscle ache, joint ache, loss of appetite, 
fatigue, or dysgeusia. However, these symptoms subsided by visit 
2, except for sore throat, which was present in one subject (2%) and 
resolved by visit 3. In arm II, eight subjects had sore throat, cough, chills, 
nausea, muscle ache, joint ache, loss of appetite, fatigue, or dysgeusia at 
visit 1. However, these symptoms subsided by visit 2, except for cough 
in one subject (2%), which resolved by visit 3 (Table 2).
Assessment of immune status based on the ISQ
Immune status was evaluated in subjects using the ISQ, based on seven 
parameters (sudden high fever, diarrhea, headache, skin problems, 
muscle and joint pain, common cold, and cough) (Table 3).
Overall well-being (SF-12 health survey)
The assessment of overall well-being (SF-12 Health Survey) was 
conducted at visit 4 (day 30). For the PCS, in arm I, the score was 
56.67±0.64, compared with 49.76±5.163 in arm II, with a statistically 
significant difference between the two groups (p<0.0001). For the 
MCS, in arm I, the score was 61.83±1.27 compared with 52.45±3.997 
in arm II. In addition, a statistically significant difference was observed 
between the two groups (p<0.0001; Table 4 and Fig. 2).
Incidence of respiratory symptoms during the study
There was no incidence of respiratory symptoms in any of the subjects 
in arm I during the study. In arm II, 4 (8%) subjects complained of 
cough (Table 5).
Table 1: Summary of demographic characteristics
Parameter Arm I (n=50) Arm II (n=50)







Gender Male 21 (42%) 18 (36%)
Female 29 (58%) 32 (64%)














Table 2: No. of subjects with symptoms 
Visits Arm I (n=50) (%) Arm II (n=50) (%)
Visit 1 10 (20) 8 (16)
Visit 2 1 (2) 1 (2)
Visit 3 0 (0) 0 (0)
Visit 4 0 (0) 0 (0)
Visit 5 0 (0) 0 (0)
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Table 3: Immune status questionnaire
Visits Arm I Arm II




























The items were scored on 5-point scale ranging from 0 to 4, with the overall 
score ranging from 0 to 8, with a higher score indicating a worse immune 
status. For comparison between groups, the Friedman test followed by Dunn’s 
multiple comparisons test and Mann–Whitney test were used. No statistically 
significant differences were observed between groups, ISQ: Immune Status 
Questionnaire.
without any sequelae. In arm II, 8 AEs were reported (cough, headache, 
and muscle and joint pain) by seven subjects (14%). These AEs were 
mild and resolved within 1–6 days, without any sequelae. None of the 
subjects withdrew due to AEs, and no serious AEs were either reported 
or observed in any of the subjects during the study period. As this 
was only a feedback study, no laboratory assessments for safety were 
performed.
All subjects adhered to the prescribed drug dosage and duration and 




Assessed for eligibility (n = 100)
Failed screening (n = 0)
Randomized (N = 100)
Arm I (n = 50)
Tab. Immusante and Tab. Guduchi Arm II (n = 50)
Follow-Up
Dropped out or withdrew consent (n = 0)Dropped out or withdrew consent (n = 0)
Study completed & analysed (n = 50) Study completed & analysed (n = 50)
Fig. 1: Flow diagram of the study design as per the Consolidated 
Standards of Reporting Trials guidelines
COVID-19 test results
A reverse-transcription polymerase chain reaction (RT-PCR) test for 
diagnosing COVID-19 was not part of the study protocol. However, 
as per the hospital COVID-19 treatment protocol, an RT-PCR test is 
mandatory for all healthcare workers who are assigned COVID-19 
ward duties. The test results of all subjects who participated in this 
study were therefore collected and evaluated retrospectively. Data 
were collected that pertain to within 1 month of the completion of 
the administration of treatment in this study. In this timeframe, only 
four subjects (8%) were found to be COVID-19 positive in arm I, 
while 13 subjects (26%) were COVID-19 positive in arm II (Table 6, 
Fig. 3).
Adverse event (AE) profile
The overall safety profile of both study drugs was found to be good 
according to the overall assessment. However, in arm I, a total of 5 AEs 
concerning abdominal pain, a burning sensation in the stomach, and 
abdominal pain with indigestion were considered as possibly related to 
the study drugs, and muscle and joint pain and headache, which were 
not considered to be related to the drugs, were reported in five subjects 
(10%). However, these AEs were mild and resolved on the same day, 
Table 4: SF-12 Health Survey and summary (visit 4)















95% CI 56.47, 56.47 44.34, 48.68
Physical role 
limitations







95% CI 56, 57.06 50.19, 52.55







95% CI 57.44, 57.44 50.28, 53.19
General 
health







95% CI 61.99, 61.99 50.04, 54.97







95% CI 66.91, 68.04 52.29, 56.08
Social 
functioning


















95% CI 54.8, 56.02 47.93, 50.59
Mental 
health





























95% CI 61.47, 62.19 51.31, 53.58
*Statistical significance in favor of arm I (statistical test: Unpaired t test, level of 
significance was P<0.05. Transformed mean was estimated for the eight SF-12 
domains, and the norm-based mean was used for the SF-12 summary measures 
(PCS and MCS). Statistical test: Unpaired t test, level of significance was  
P < 0.05, ns: not significant, BG: between groups. The SF12 data calculates two 
summary component scores, the PCS and MCS, with eight sub-domains made 
up of 12 questions in total. Scores range from 0 to 100, where a zero indicates 
the poorest health and 100 indicates most healthy. The PCS and MCS combine 
the 12 responses in such a way that they compare to the national norm, with a 
mean score of 50.0 and a standard deviation of 10.
Table 5: Respiratory symptoms n (%)
Symptoms Arm 1(n = 50) Arm 2 (n = 50)
Cough 0 (0%) 4 (8%)
141
Asian J Pharm Clin Res, Vol 14, Issue 8, 2021, 138-142
 Jayanthi et al.
Table 6: COVID-19 test results
Outcome Arm I (%) Arm II (%)
Positive 4 (8) 13 (26)
Negative 46 (92) 37 (74)
Table 7: AEs
Description Total Arm I (n=50) Arm II (n=50)
Number of AEs 13 5 8
Number of subjects 
with AEs-n (%)
12 5 (10%) 7 (14%)
AE details
Cough 4 0 4
Headache 4 1 3
Abdominal pain 1 1 –
Burning sensation in 
stomach
1 1 –
Abdominal pain with 
indigestion
1 1 –
Muscle and joint pain 2 1 1
AE: Adverse event.
significant alterations in vital parameters (pulse, respiratory rate, blood 
pressure, and temperature) or any change in the subjects’ medical 
history or condition. Thus, both the herbal formulations were well 
tolerated and found to be safe (Table 7).
DISCUSSION
The COVID-19 pandemic has resulted in severe health consequences. 
Healthcare workers in particular have additional stressors during 
patient care such as physical strain, isolation, stringent adherence to 
infection control procedures, and fears about contracting the infection. 
Healthcare workers have been found to be socially affected due to their 
close association with the management of COVID-19 [4].
Tillu et al. enumerated the concepts behind and practices around 
Ayurveda, that may help manage COVID-19. Integrating the concepts of 
Ayurveda and yoga with that of modern medicine could be an effective 
approach toward the overall management of COVID-19, including for the 
prevention, treatment, and rehabilitation of subjects [5]. Based on their 
research, Tillu et al. suggested that to strengthen immunity, multiple 
botanicals that are described in Ayurveda should be used in clinical 
practice, as they have been in use as medicinal agents for centuries. 
The authors showed that these botanicals could be considered for the 
prophylaxis of COVID-19 and as an adjuvant therapy [6]. The selection 
of products for our study was in line with this concept.
None of the subjects in arm I experienced any respiratory symptoms, 
but 8% of the subjects in arm II had a cough. These findings indicate 
that the administration of Immusante and Guduchi tablets had 
additional benefits in contributing to the non-occurrence/recurrence 
of respiratory symptoms during the study.
Immune status was evaluated in subjects by the ISQ, which is a well-
validated, easily implementable, short, and cost-effective ISQ, with 
applicability in multiple settings, including in clinical practice, research, 
and self-assessment [7,8]. In this study, immune status was rated higher 
in arm I compared to arm II.
In addition, the overall well-being of subjects in this study was assessed 
through the SF-12 Health Survey, which is widely used and is validated 
for investigating health-related quality of life in a variety of both acute 
and chronic conditions. Many studies suggest the results of an SF-12 
questionnaire demonstrated significant improvements in physical 
and mental functioning at the end of the study [9-12]. The outcome in 
this study is in line with the therapeutic properties of Immusante and 
Guduchi for enhancing overall well-being.
Ongoing assessment of clinical symptoms is an important aspect of 
managing the COVID-19 pandemic in terms of prevention as well as 
ameliorating existing symptoms. As all participants in this study were 
initially healthy, they were expected to recover from mild symptoms 
on their own. However, considering the properties of Immusante and 
Guduchi, these may have helped to boost immunity. The safety findings 
in this study are in line with the known safety profiles of these products, 
which have been on the market for many years without any important 
safety concerns.
In terms of prevention, the prevalence of COVID-19 infection has 
been reported to be 2,747 cases per 100,000 frontline health care 
workers compared with 242 cases per 100,000 people in the general 
community [13]. Another study revealed that among 95% of infected 
health care workers who were assigned to a non-COVID-19 facility, 
72% reported exposure to a coworker or patient as the source of 
infection [14]. Considering the high incidence of COVID-19 infection 
among healthcare workers, the available data in this study are 
encouraging. Our results according to COVID-19 tests post-study 
showed that 8% of subjects were COVID-19-positive in arm I compared 
with 26% of subjects in arm II. Although the sample size in this study 
is small for a prevention study, our preliminary data on the benefits of 
Immusante and Guduchi treatment are noteworthy. Further studies 
with a longer duration of intervention and a larger study population are 
needed to validate this outcome, which may pose significant benefits to 
high-risk healthcare workers.
Aside from its limitations, including the inclusion of healthcare 
professionals in various roles using a variety of protective equipment, 
the use of open-label drugs, the measurement of results by subjective 
questionnaires, and the small sample size, this study has some 
advantages. For instance, this study was conducted at a reputed medical 
institute (the only dedicated COVID-19 treatment facility in the state 
at the time this study was conducted) after approval from the ethics 
committee of the institute and registration in Clinical Trials Registry 
of India. In addition, the ISQ and SF-12 Health Survey are validated 
Fig. 3: COVID-19 test results
Fig. 2: Short form 12 health survey (PCS and MCS)
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questionnaires recommended by the WHO for assessments in this type 
of study.
CONCLUSION
This clinical study demonstrates that treatment with a combination of 
herbal formulations of Immusante and Guduchi tablets in a group of 
healthcare workers at a high risk of contracting COVID-19 infection had 
a beneficial effect in boosting their overall health. This is supported by 
the outcome that no subjects in arm I reported respiratory symptoms 
compared with four subjects (8%) who reported cough in arm II. In 
addition, only 8% of subjects were diagnosed with COVID-19 in arm 
I compared with 26% subjects in arm II. Thus, it can be inferred that 
a combination of Immusante and Guduchi tablets may be beneficial in 
protecting high-risk healthcare workers from contracting COVID-19 
infection. Subjects in both study arms showed similar status in terms 
of the ISQ; however, a better trend was observed in arm I compared 
with that in arm II. In the SF-12 Health Survey results, a statistically 
significant difference was observed in arm I compared with that in arm 
II, demonstrating a better health status in subjects who were treated 
on Immusante and Guduchi tablets compared with that of subjects in 
the control arm. In addition, there were few AEs and those that were 
reported were mild in nature and resolved without any sequalae, 
indicating that these herbal formulations are safe and well tolerated.
Considering the efficacy and safety of our study results, the Immusante 
and Guduchi combination may be recommended for boosting the 
immunity and overall health of health care workers (including high-risk 
personnel who are assigned to COVID-19 wards) for the prevention of 
respiratory symptoms, protection from contracting COVID-19 infection, 
and improving their overall physical and mental well-being. Further 
collection of data in a large population is warranted to corroborate our 
findings.
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